• Published On : Apr-2017 |
  • Pages : 184 Pages |
  • Format :

1. Executive Summary

2. Immuno-Oncology Market Introduction
   2.1. Market Introduction and Definitions
   2.2. Market Taxonomy

3. Global Immuno-Oncology Market Analysis Scenario
   3.1. Market Scenario (US$ Mn) Forecast
   3.2. Market Size (US$ Mn) and Forecast
        3.2.1. Market Value (US$ Mn) and Y-o-Y Growth
        3.2.2. Absolute $ Opportunity
   3.3. Key Market Developments
   3.4. Cancer Epidemiology, by Region
   3.5. Regulatory Scenario
   3.6. Patient Support Programs
   3.7. Pipeline Snapshot

4. Market Dynamics
   4.1. Macro-economic Factors
   4.2. Drivers
        4.2.1. Supply Side
        4.2.2. Demand Side
   4.3. Restraints
   4.4. Opportunity
   4.5. Trends

5. Global Immuno-Oncology Market Analysis and Forecasts, By Therapy Type
   5.1. Introduction
   5.2. Basis Point Share (BPS) Analysis By Therapy Type
   5.3. Y-o-Y Growth Projections By Therapy Type
   5.4. Market Value Forecast By Therapy Type, 2017–2025
        5.4.1. Immune Checkpoint Inhibitors
               5.4.1.1. PD-1
               5.4.1.2. PD-L1
               5.4.1.3. CTLA-4
        5.4.2. Immune System Modulators
        5.4.3. Cancer Vaccines
        5.4.4. Oncolytic Virus
        5.4.5. Other Therapies
   5.5. Market Attractiveness By Therapy Type

6. Global Immuno-Oncology Market Analysis and Forecasts, By Therapeutic Area
   6.1. Introduction
   6.2. Basis Point Share (BPS) Analysis By Therapeutic Area
   6.3. Y-o-Y Growth Projections By Therapeutic Area
   6.4. Market Value Forecast By Therapeutic Area, 2017–2025
        6.4.1. Melanoma
        6.4.2. Lung Cancer
        6.4.3. Blood Cancers
        6.4.4. Renal Cell Carcinoma
        6.4.5. Prostate Cancer
        6.4.6. Bladder Cancer
        6.4.7. Other Cancers
   6.5. Market Attractiveness By Therapeutic Area

7. Global Immuno-Oncology Market Analysis and Forecasts, By End User
   7.1. Introduction
   7.2. Basis Point Share (BPS) Analysis By End User
   7.3. Y-o-Y Growth Projections By End User
   7.4. Market Value Forecast By End User, 2017–2025
        7.4.1. Hospitals
        7.4.2. Clinics
        7.4.3. Ambulatory Surgical Centers
   7.5. Market Attractiveness By End User

8. Global Immuno-Oncology Market Analysis and Forecasts, By Region
   8.1. Basis Point Share (BPS) Analysis By Region
   8.2. Y-o-Y Growth Projections By Region
   8.3. Market Value Forecast By Region
        8.3.1. North America
        8.3.2. Latin America
        8.3.3. Europe
        8.3.4. Asia Pacific
        8.3.5. Middle East and Africa
   8.4. Market Attractiveness By Region

9. North America Immuno-Oncology Market Analysis and Forecast
   9.1. Introduction
        9.1.1. Basis Point Share (BPS) Analysis By Country
        9.1.2. Y-o-Y Growth Projections By Country
   9.2. Market Value Forecast By Therapy Type, 2017–2025
        9.2.1. Immune Checkpoint Inhibitors
               9.2.1.1. PD-1
               9.2.1.2. PD-L1
               9.2.1.3. CTLA-4
        9.2.2. Immune System Modulators
        9.2.3. Cancer Vaccines
        9.2.4. Oncolytic Virus
        9.2.5. Other Therapies
   9.3. Market Value Forecast By Therapeutic Area, 2017–2025
        9.3.1. Melanoma
        9.3.2. Lung Cancer
        9.3.3. Blood Cancers
        9.3.4. Renal Cell Carcinoma
        9.3.5. Prostate Cancer
        9.3.6. Bladder Cancer
        9.3.7. Other Cancers
   9.4. Market Value Forecast By End User, 2017–2025
        9.4.1. Hospitals
        9.4.2. Clinics
        9.4.3. Ambulatory Surgical Centers
   9.5. Market Value Forecast By Country, 2017–2025
        9.5.1. U.S.
        9.5.2. Canada
   9.6. Market Attractiveness Analysis
        9.6.1. By Therapy Type
        9.6.2. By Therapeutic Area
        9.6.3. By End User
        9.6.4. By Country
   9.7. Drivers and Restraints: Impact Analysis

10. Latin America Immuno-Oncology Market Analysis and Forecast
   10.1.Introduction
        10.1.1. Basis Point Share (BPS) Analysis By Country
        10.1.2. Y-o-Y Growth Projections By Country
   10.2.Market Value Forecast By Therapy Type, 2017–2025
        10.2.1. Immune Checkpoint Inhibitors
               10.2.1.1. PD-1
               10.2.1.2. PD-L1
               10.2.1.3. CTLA-4
        10.2.2. Immune System Modulators
        10.2.3. Cancer Vaccines
        10.2.4. Oncolytic Virus
        10.2.5. Other Therapies
   10.3.Market Value Forecast By Therapeutic Area, 2017–2025
        10.3.1. Melanoma
        10.3.2. Lung Cancer
        10.3.3. Blood Cancers
        10.3.4. Renal Cell Carcinoma
        10.3.5. Prostate Cancer
        10.3.6. Bladder Cancer
        10.3.7. Other Cancers
   10.4.Market Value Forecast By End User, 2017–2025
        10.4.1. Hospitals
        10.4.2. Clinics
        10.4.3. Ambulatory Surgical Centers
   10.5.Market Value Forecast By Country, 2017–2025
        10.5.1. Brazil
        10.5.2. Mexico
        10.5.3. Rest of Latin America
   10.6.Market Attractiveness Analysis
        10.6.1. By Therapy Type
        10.6.2. By Therapeutic Area
        10.6.3. By End User
        10.6.4. By Country
   10.7. Drivers and Restraints: Impact Analysis

11. Europe Immuno-Oncology Market Analysis and Forecast
   11.1.Introduction
        11.1.1. Basis Point Share (BPS) Analysis By Country
        11.1.2. Y-o-Y Growth Projections By Country
   11.2.Market Value Forecast By Therapy Type, 2017–2025
        11.2.1. Immune Checkpoint Inhibitors
               11.2.1.1. PD-1
               11.2.1.2. PD-L1
               11.2.1.3. CTLA-4
        11.2.2. Immune System Modulators
        11.2.3. Cancer Vaccines
        11.2.4. Oncolytic Virus
        11.2.5. Other Therapies
   11.3.Market Value Forecast By Therapeutic Area, 2017–2025
        11.3.1. Melanoma
        11.3.2. Lung Cancer
        11.3.3. Blood Cancers
        11.3.4. Renal Cell Carcinoma
        11.3.5. Prostate Cancer
        11.3.6. Bladder Cancer
        11.3.7. Other Cancers
   11.4.Market Value Forecast By End User, 2017–2025
        11.4.1. Hospitals
        11.4.2. Clinics
        11.4.3. Ambulatory Surgical Centers
   11.5.Market Value Forecast By Country, 2017–2025
        11.5.1. Germany
        11.5.2. U.K.
        11.5.3. Italy
        11.5.4. France
        11.5.5. Spain
        11.5.6. Rest of Europe
   11.6.Market Attractiveness Analysis
        11.6.1. By Therapy Type
        11.6.2. By Therapeutic Area
        11.6.3. By End User
        11.6.4. By Country
   11.7. Drivers and Restraints: Impact Analysis

12. Asia Pacific Immuno-Oncology Market Analysis and Forecast
   12.1.Introduction
        12.1.1. Basis Point Share (BPS) Analysis By Country
        12.1.2. Y-o-Y Growth Projections By Country
   12.2.Market Value Forecast By Therapy Type, 2017–2025
        12.2.1. Immune Checkpoint Inhibitors
               12.2.1.1. PD-1
               12.2.1.2. PD-L1
               12.2.1.3. CTLA-4
        12.2.2. Immune System Modulators
        12.2.3. Cancer Vaccines
        12.2.4. Oncolytic Virus
        12.2.5. Other Therapies
   12.3.Market Value Forecast By Therapeutic Area, 2017–2025
        12.3.1. Melanoma
        12.3.2. Lung Cancer
        12.3.3. Blood Cancers
        12.3.4. Renal Cell Carcinoma
        12.3.5. Prostate Cancer
        12.3.6. Bladder Cancer
        12.3.7. Other Cancers
   12.4.Market Value Forecast By End User, 2017–2025
        12.4.1. Hospitals
        12.4.2. Clinics
        12.4.3. Ambulatory Surgical Centers
   12.5.Market Value Forecast By Country, 2017–2025
        12.5.1. Japan
        12.5.2. South Korea
        12.5.3. Australia & New Zealand
        12.5.4. China
        12.5.5. Rest of Asia Pacific
   12.6.Market Attractiveness Analysis
        12.6.1. By Therapy Type
        12.6.2. By Therapeutic Area
        12.6.3. By End User
        12.6.4. By Country
   12.7. Drivers and Restraints: Impact Analysis

13. Middle East and Africa Immuno-Oncology Market Analysis and Forecast
   13.1.Introduction
        13.1.1. Basis Point Share (BPS) Analysis By Country
        13.1.2. Y-o-Y Growth Projections By Country
   13.2.Market Value Forecast By Therapy Type, 2017–2025
        13.2.1. Immune Checkpoint Inhibitors
               13.2.1.1. PD-1
               13.2.1.2. PD-L1
               13.2.1.3. CTLA-4
        13.2.2. Immune System Modulators
        13.2.3. Cancer Vaccines
        13.2.4. Oncolytic Virus
        13.2.5. Other Therapies
   13.3.Market Value Forecast By Therapeutic Area, 2017–2025
        13.3.1. Melanoma
        13.3.2. Lung Cancer
        13.3.3. Blood Cancers
        13.3.4. Renal Cell Carcinoma
        13.3.5. Prostate Cancer
        13.3.6. Bladder Cancer
        13.3.7. Other Cancers
   13.4.Market Value Forecast By End User, 2017–2025
        13.4.1. Hospitals
        13.4.2. Clinics
        13.4.3. Ambulatory Surgical Centers
   13.5.Market Value Forecast By Country, 2017–2025
        13.5.1. South Africa
        13.5.2. GCC Countries
        13.5.3. Rest of Middle East & Africa
   13.6.Market Attractiveness Analysis
        13.6.1. By Therapy Type
        13.6.2. By Therapeutic Area
        13.6.3. By End User
        13.6.4. By Country
   13.7. Drivers and Restraints: Impact Analysis

14. Competition Landscape
   14.1. Market Share Analysis By Company (2016)
   14.2. Company Profiles (Details – Overview, Financials, Strategy, Recent Developments)
        14.2.1. Amgen, Inc.
        14.2.2. AstraZeneca Plc
        14.2.3. Bristol-Myers Squibb Company
        14.2.4. Dendreon Corporation
        14.2.5. F. Hoffmann-La Roche
        14.2.6. Merck & Co., Inc.
        14.2.7. Novartis AG
        14.2.8. Pfizer, Inc.
        14.2.9. Sanofi

15. Assumptions and Acronyms Used

16. Research Methodology


List of Tables

Table 01 : Global Immuno-Oncology Market Value (US$ Mn) Analysis and Forecast By Therapy Type, 2016–2025
Table 02 : Global Immuno-Oncology Market Value (US$ Mn) Analysis and Forecast By Therapeutic Area, 2016–2025
Table 03 : Global Immuno-Oncology Market Value (US$ Mn) Analysis and Forecast By End User, 2016–2025
Table 04 : Global Immuno-Oncology Market Value (US$ Mn) Analysis and Forecast By Region, 2016–2025
Table 05 : North America Immuno-Oncology Market Value (US$ Mn) Analysis and Forecast By Therapy Type, 2016–2025
Table 06 : North America Immuno-Oncology Market Value (US$ Mn) Analysis and Forecast By Therapeutic Area, 2016–2025
Table 07 : North America Immuno-Oncology Market Value (US$ Mn) Analysis and Forecast By End User, 2016–2025
Table 08 : North America Immuno-Oncology Market Value (US$ Mn) Analysis and Forecast By Country, 2016–2025
Table 09 : Latin America Immuno-Oncology Market Value (US$ Mn) Analysis and Forecast By Therapy Type, 2016–2025
Table 10 : Latin America Immuno-Oncology Market Value (US$ Mn) Analysis and Forecast By Therapeutic Area, 2016–2025
Table 11 : Latin America Immuno-Oncology Market Value (US$ Mn) Analysis and Forecast By End User, 2016–2025
Table 12 : Latin America Immuno-Oncology Market Value (US$ Mn) Analysis and Forecast By Country, 2016–2025
Table 13 : Europe Immuno-Oncology Market Value (US$ Mn) Analysis and Forecast By Therapy Type, 2016–2025
Table 14 : Europe Immuno-Oncology Market Value (US$ Mn) Analysis and Forecast By Therapeutic Area, 2016–2025
Table 15 : Europe Immuno-Oncology Market Value (US$ Mn) Analysis and Forecast By End User, 2016–2025
Table 16 : Europe Immuno-Oncology Market Value (US$ Mn) Analysis and Forecast By Country, 2016–2025
Table 17 : Asia Pacific Immuno-Oncology Market Value (US$ Mn) Analysis and Forecast By Therapy Type, 2016–2025
Table 18 : Asia Pacific Immuno-Oncology Market Value (US$ Mn) Analysis and Forecast By Therapeutic Area, 2016–2025
Table 19 : Asia Pacific Immuno-Oncology Market Value (US$ Mn) Analysis and Forecast By End User, 2016–2025
Table 20 : Asia Pacific Immuno-Oncology Market Value (US$ Mn) Analysis and Forecast By Country, 2016–2025
Table 21 : Middle East & Africa Immuno-Oncology Market Value (US$ Mn) Analysis and Forecast By Therapy Type, 2016–2025
Table 22 : Middle East & Africa Immuno-Oncology Market Value (US$ Mn) Analysis and Forecast By Therapeutic Area, 2016–2025
Table 23 : Middle East & Africa Immuno-Oncology Market Value (US$ Mn) Analysis and Forecast By End User, 2016–2025
Table 24 : Middle East & Africa Immuno-Oncology Market Value (US$ Mn) Analysis and Forecast By Country, 2016–2025


List of Figures

Figure 01 : Global Immuno-Oncology Market – Scenario Forecast, 2016–2025 (US$ Mn)
Figure 02 : Global Immuno-Oncology Market Value (US$ Mn) & Y-o-Y Growth (%), 2016–2025
Figure 03 : Global Immuno-Oncology Market Absolute $ Opportunity, 2017–2025
Figure 04 : Global Immuno-Oncology Market Share Analysis (%) By Therapy Type, 2017 & 2025
Figure 05 : Global Immuno-Oncology Y-o-Y growth (%) By Therapy Type, 2017–2025
Figure 06 : Global Immuno-Oncology Market Value (US$ Mn) & Y-o-Y Growth (%) By Immune Checkpoint Inhibitors Segment, 2016–2025
Figure 07 : Global Immuno-Oncology Market Absolute $ Opportunity (US$ Mn) By Immune Checkpoint Inhibitors Segment, 2017–2025
Figure 08 : Global Immuno-Oncology Market Share Analysis (%) By Immune Checkpoint Inhibitors Therapy Type, 2017 & 2025
Figure 09 : Global Immuno-Oncology Y-o-Y growth (%) By Immune Checkpoint Inhibitors Therapy Type, 2017–2025
Figure 10 : Global Immuno-Oncology Market Value (US$ Mn) & Y-o-Y Growth (%) By Immune System Modulators Segment, 2016–2025
Figure 11 : Global Immuno-Oncology Market Absolute $ Opportunity (US$ Mn) By Immune System Modulators Segment, 2017–2025
Figure 12 : Global Immuno-Oncology Market Value (US$ Mn) & Y-o-Y Growth (%) By Cancer Vaccines Segment, 2016–2025
Figure 13 : Global Immuno-Oncology Market Absolute $ Opportunity (US$ Mn) By Cancer Vaccines Segment, 2017–2025
Figure 14 : Global Immuno-Oncology Market Value (US$ Mn) & Y-o-Y Growth (%) By Oncolytic Virus Segment, 2016–2025
Figure 15 : Global Immuno-Oncology Market Absolute $ Opportunity (US$ Mn) By Oncolytic Virus Segment, 2017–2025
Figure 16 : Global Immuno-Oncology Market Value (US$ Mn) & Y-o-Y Growth (%) By Other Therapies Segment, 2016–2025
Figure 17 : Global Immuno-Oncology Market Absolute $ Opportunity (US$ Mn) By Other Therapies Segment, 2017–2025
Figure 18 : Global Immuno-Oncology Market Attractiveness Analysis By Therapy Type, 2017–2025
Figure 19 : Global Immuno-Oncology Market Share Analysis (%) By Therapeutic Area, 2017 & 2025
Figure 20 : Global Immuno-Oncology Y-o-Y growth (%) By Therapeutic Area, 2017–2025
Figure 21 : Global Immuno-Oncology Market Value (US$ Mn) & Y-o-Y Growth (%) By Melanoma Therapeutic Area, 2016–2025
Figure 22 : Global Immuno-Oncology Market Absolute $ Opportunity (US$ Mn) By Melanoma Therapeutic Area, 2017–2025
Figure 23 : Global Immuno-Oncology Market Value (US$ Mn) & Y-o-Y Growth (%) By Lung Cancer Therapeutic Area, 2016–2025
Figure 24 : Global Immuno-Oncology Market Absolute $ Opportunity (US$ Mn) By Lung Cancer Therapeutic Area, 2017–2025
Figure 25 : Global Immuno-Oncology Market Value (US$ Mn) & Y-o-Y Growth (%) By Blood Cancers Therapeutic Area, 2016–2025
Figure 26 : Global Immuno-Oncology Market Absolute $ Opportunity (US$ Mn) By Blood Cancers Therapeutic Area, 2017–2025
Figure 27 : Global Immuno-Oncology Market Value (US$ Mn) & Y-o-Y Growth (%) By Renal Cell Carcinoma Therapeutic Area, 2016–2025
Figure 28 : Global Immuno-Oncology Market Absolute $ Opportunity (US$ Mn) By Renal Cell Carcinoma Therapeutic Area, 2017–2025
Figure 29 : Global Immuno-Oncology Market Value (US$ Mn) & Y-o-Y Growth (%) By Prostate Cancer Therapeutic Area, 2016–2025
Figure 30 : Global Immuno-Oncology Market Absolute $ Opportunity (US$ Mn) By Prostate Cancer Therapeutic Area, 2017–2025
Figure 31 : Global Immuno-Oncology Market Value (US$ Mn) & Y-o-Y Growth (%) By Bladder Cancer Therapeutic Area, 2016–2025
Figure 32 : Global Immuno-Oncology Market Absolute $ Opportunity (US$ Mn) By Bladder Cancer Therapeutic Area, 2017–2025
Figure 33 : Global Immuno-Oncology Market Value (US$ Mn) & Y-o-Y Growth (%) By Other Cancers Therapeutic Area, 2016–2025
Figure 34 : Global Immuno-Oncology Market Absolute $ Opportunity (US$ Mn) By Other Cancers Therapeutic Area, 2017–2025
Figure 35 : Global Immuno-Oncology Market Attractiveness Analysis By Therapeutic Area, 2017–2025
Figure 36 : Global Immuno-Oncology Market Share Analysis (%) By End User, 2017 & 2025
Figure 37 : Global Immuno-Oncology Y-o-Y growth (%) By End User, 2017–2025
Figure 38 : Global Immuno-Oncology Market Value (US$ Mn) & Y-o-Y Growth (%) By Hospitals End User Segment, 2016–2025
Figure 39 : Global Immuno-Oncology Market Absolute $ Opportunity (US$ Mn) By Hospitals End User Segment, 2017–2025
Figure 40 : Global Immuno-Oncology Market Value (US$ Mn) & Y-o-Y Growth (%) By Clinics End User Segment, 2016–2025
Figure 41 : Global Immuno-Oncology Market Absolute $ Opportunity (US$ Mn) By Clinics End User Segment, 2017–2025
Figure 42 : Global Immuno-Oncology Market Value (US$ Mn) & Y-o-Y Growth (%) By Ambulatory Surgical Centers End User Segment, 2016–2025
Figure 43 : Global Immuno-Oncology Market Absolute $ Opportunity (US$ Mn) By Ambulatory Surgical Centers End User Segment, 2017–2025
Figure 44 : Global Immuno-Oncology Market Attractiveness Analysis By End User, 2017–2025
Figure 45 : Global Immuno-Oncology Market Value (US$ Mn) and CAGR (%) By Region, 2016, 2021, and 2025
Figure 46 : Global Immuno-Oncology Market Share Analysis (%) By Region, 2017 & 2025
Figure 47 : Global Immuno-Oncology Y-o-Y growth (%) By Region, 2017–2025
Figure 48 : North America Immuno-Oncology Market Value (US$ Mn) & Y-o-Y Growth (%), 2016–2025
Figure 49 : North America Immuno-Oncology Market Absolute $ Opportunity (US$ Mn), 2017–2025
Figure 50 : Latin America Immuno-Oncology Market Value (US$ Mn) & Y-o-Y Growth (%), 2016–2025
Figure 51 : Latin America Immuno-Oncology Market Absolute $ Opportunity (US$ Mn), 2017–2025
Figure 52 : Europe Immuno-Oncology Market Value (US$ Mn) & Y-o-Y Growth (%), 2016–2025
Figure 53 : Europe Immuno-Oncology Market Absolute $ Opportunity (US$ Mn), 2017–2025
Figure 54 : Asia Pacific Immuno-Oncology Market Value (US$ Mn) & Y-o-Y Growth (%), 2016–2025
Figure 55 : Asia Pacific Immuno-Oncology Market Absolute $ Opportunity (US$ Mn), 2017–2025
Figure 56 : Middle East & Africa Immuno-Oncology Market Value (US$ Mn) & Y-o-Y Growth (%), 2016–2025
Figure 57 : Middle East & Africa Immuno-Oncology Market Absolute $ Opportunity (US$ Mn), 2017–2025
Figure 58 : Global Immuno-Oncology Market Attractiveness Analysis By Region, 2017–2025
Figure 59 : North America Immuno-Oncology Market Share Analysis (%) By Therapy Type, 2017 & 2025
Figure 60 : North America Immuno-Oncology Y-o-Y growth (%) By Therapy Type, 2017–2025
Figure 61 : North America Immuno-Oncology Market Share Analysis (%) By Country, 2017 & 2025
Figure 62 : North America Immuno-Oncology Market Attractiveness Analysis By Country, 2017–2025
Figure 63 : North America Immuno-Oncology Y-o-Y growth (%) By Country, 2017–2025

Figure 64 : North America Immuno-Oncology Market Attractiveness Analysis By Therapy Type, 2017–2025
Figure 65 : North America Immuno-Oncology Market Attractiveness Analysis By Therapeutic Area, 2017–2025
Figure 66 : North America Immuno-Oncology Market Attractiveness Analysis By End User, 2017–2025
Figure 67 : Latin America Immuno-Oncology Market Share Analysis (%) By Therapy Type, 2017 & 2025
Figure 68 : Latin America Immuno-Oncology Y-o-Y growth (%) By Therapy Type, 2017–2025
Figure 69 : Latin America Immuno-Oncology Market Share Analysis (%) By Country, 2017 & 2025
Figure 70 : Latin America Immuno-Oncology Market Attractiveness Analysis By Country, 2017–2025
Figure 71 : Latin America Immuno-Oncology Y-o-Y growth (%) By Country, 2017–2025

Figure 72 : Latin America Immuno-Oncology Market Attractiveness Analysis By Therapy Type, 2017–2025
Figure 73 : Latin America Immuno-Oncology Market Attractiveness Analysis By Therapeutic Area, 2017–2025
Figure 74 : Latin America Immuno-Oncology Market Attractiveness Analysis By End User, 2017–2025
Figure 75 : Europe Immuno-Oncology Market Share Analysis (%) By Therapy Type, 2017 & 2025
Figure 76 : Europe Immuno-Oncology Y-o-Y growth (%) By Therapy Type, 2017–2025
Figure 77 : Europe Immuno-Oncology Market Share Analysis (%) By Country, 2017 & 2025
Figure 78 : Europe Immuno-Oncology Market Attractiveness Analysis By Country, 2017–2025
Figure 79 : Europe Immuno-Oncology Y-o-Y growth (%) By Country, 2017–2025
Figure 80 : Europe Immuno-Oncology Market Attractiveness Analysis By Therapy Type, 2017–2025
Figure 81 : Europe Immuno-Oncology Market Attractiveness Analysis By Therapeutic Area, 2017–2025
Figure 82 : Europe Immuno-Oncology Market Attractiveness Analysis By End User, 2017–2025
Figure 83 : Asia Pacific Immuno-Oncology Market Share Analysis (%) By Therapy Type, 2017 & 2025
Figure 84 : Asia Pacific Immuno-Oncology Y-o-Y growth (%) By Therapy Type, 2017–2025
Figure 85 : Asia Pacific Immuno-Oncology Market Share Analysis (%) By Country, 2017 & 2025
Figure 86 : Asia Pacific Immuno-Oncology Market Attractiveness Analysis By Country, 2017–2025
Figure 87 : Asia Pacific Immuno-Oncology Y-o-Y growth (%) By Country, 2017–2025
Figure 88 : Asia Pacific Immuno-Oncology Market Attractiveness Analysis By Therapy Type, 2017–2025
Figure 89 : Asia Pacific Immuno-Oncology Market Attractiveness Analysis By Therapeutic Area, 2017–2025
Figure 90 : Asia Pacific Immuno-Oncology Market Attractiveness Analysis By End User, 2017–2025
Figure 91 : Middle East & Africa Immuno-Oncology Market Share Analysis (%) By Therapy Type, 2017 & 2025
Figure 92 : Middle East & Africa Immuno-Oncology Y-o-Y growth (%) By Therapy Type, 2017–2025
Figure 93 : Middle East & Africa Immuno-Oncology Market Share Analysis (%) By Country, 2017 & 2025
Figure 94 : Middle East & Africa Immuno-Oncology Market Attractiveness Analysis By Country, 2017–2025
Figure 95 : Middle East & Africa Immuno-Oncology Y-o-Y growth (%) By Country, 2017–2025
Figure 96 : Middle East & Africa Immuno-Oncology Market Attractiveness Analysis By Therapy Type, 2017–2025
Figure 97 : Middle East & Africa Immuno-Oncology Market Attractiveness Analysis By Therapeutic Area, 2017–2025
Figure 98 : Middle East & Africa Immuno-Oncology Market Attractiveness Analysis By End User, 2017–2025
Figure 99 : Global Immuno-Oncology Company Market Share Analysis, 2016